Soliris 300mg Injection

Soliris 300mg Injection contains active ingredient Eculizumab which is a recombinant humanized monoclonal antibody. Doctor prescribes this injection to treat rare blood disorders including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalised myasthenia gravis (gMG).

It acts by blocking the complement protein C5 in the immune system. It should be administered by a doctor or experienced nurse. Don't self administer the injection.

​

• Paroxysmal Nocturnal Hemoglobinuria (PNH)

• Atypical Hemolytic Uremic Syndrome (aHUS)

• Generalised Myasthenia Gravis (gMG)

• Prevention of Complement-Mediated Organ Damage

• Other Rare Complement-Mediated Disorders

Like any other medicine, Soliris 300mg Injection also shows some side effects. Some of the mild ones do not need any medical attention, and they go away as the body adapts to the medicine. It is important to consult your doctor if they persist for a longer time and are deteriorating your health.
Common side effects include:

• Headache

• Fatigue

• Nausea

• Diarrhea

• Fever or mild chills

• Dizziness

• Cough or mild shortness of breath

• Skin rash or redness at the injection site

• Soliris 300mg is available in injection form and is advised to be taken as per the doctor's prescription. It can only be given intravenously by a doctor or nurse under strict medical supervision.
• Taking this injection in the wrong way may give you severe side effects. In case of overdose, contact your healthcare provider or doctor and they will provide you with medical attention.
• Missing or overdosing will impact the overall health of the patients and may also have side effects. So, it is always advisable to follow the prescription of the doctor strictly.

​If you skip a dose of Soliris injection, you must ask your doctor about the best ways to cope with it. Your therapy may require rescheduling.​

• Keating, G. M. (2013). Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs, 73(18), 2053-2066. https://pubmed.ncbi.nlm.nih.gov/24249647/

• Gruppo, R. A., & Rother, R. P. (2009). Eculizumab for congenital atypical hemolytic–uremic syndrome. New England Journal of Medicine, 360(5), 544-546. https://pubmed.ncbi.nlm.nih.gov/19179329/

• Engel, E. R., & Walter, J. E. (2020). Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs. Hematology 2014, the American Society of Hematology Education Program Book, 2020(1), 312-318. https://pubmed.ncbi.nlm.nih.gov/33275746/

• Paul, F. (2013). Hope for a rare disease: eculizumab in neuromyelitis optica. The Lancet Neurology, 12(6), 529-531. https://pubmed.ncbi.nlm.nih.gov/23623398/

• Parker, C. J., Kar, S., & Kirkpatrick, P. (2007). Eculizumab. Nature Reviews Drug Discovery, 6(7), 515-516.